197 related articles for article (PubMed ID: 35479595)
21. Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience.
Tan B; Yang JC; Young CL; Bishu S; Owyang SY; El-Zaatari M; Zhang M; Grasberger H; Qian JM; Kao JY
Dig Dis Sci; 2018 Feb; 63(2):437-445. PubMed ID: 29264696
[TBL] [Abstract][Full Text] [Related]
22. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced?
Baylina M; Muñoz N; Sánchez-Delgado J; López-Góngora S; Calvet X; Puig I
Helicobacter; 2019 Jun; 24(3):e12584. PubMed ID: 30990575
[TBL] [Abstract][Full Text] [Related]
23. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective?
Breuer T; Graham DY
Am J Gastroenterol; 1999 Mar; 94(3):725-9. PubMed ID: 10086658
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial susceptibility testing before first-line treatment for
Cosme A; Montes M; Ibarra B; Tamayo E; Alonso H; Mendarte U; Lizasoan J; Herreros-Villanueva M; Bujanda L
World J Gastroenterol; 2017 May; 23(18):3367-3373. PubMed ID: 28566898
[TBL] [Abstract][Full Text] [Related]
25. Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children.
Kotilea K; Mekhael J; Salame A; Mahler T; Miendje-Deyi VY; Cadranel S; Bontems P
Helicobacter; 2017 Aug; 22(4):. PubMed ID: 28303625
[TBL] [Abstract][Full Text] [Related]
26. Antibiotic resistances and eradication rates in Helicobacter pylori infection.
Botija G; García Rodríguez C; Recio Linares A; Campelo Gutiérrez C; Pérez-Fernández E; Barrio Merino A
An Pediatr (Engl Ed); 2021 Dec; 95(6):431-437. PubMed ID: 34810153
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of a multistep strategy for Helicobacter pylori eradication.
Gasbarrini A; Ojetti V; Armuzzi A; Branca G; Canducci F; Torre ES; Candelli M; Pastorelli A; Anti M; Fedeli G; Fadda G; Pola P; Gasbarrini G
Aliment Pharmacol Ther; 2000 Jan; 14(1):79-83. PubMed ID: 10632649
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Potential of Sitafloxacin as a New Drug Candidate for
Choi YI; Lee SM; Chung JW; Kim KO; Kwon KA; Kim YJ; Kim JH; Lee SM; Jeong JY; Park DK
Antibiotics (Basel); 2021 Oct; 10(10):. PubMed ID: 34680822
[TBL] [Abstract][Full Text] [Related]
29. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.
Gisbert JP; Gisbert JL; Marcos S; Jimenez-Alonso I; Moreno-Otero R; Pajares JM
Aliment Pharmacol Ther; 2008 Feb; 27(4):346-54. PubMed ID: 17999716
[TBL] [Abstract][Full Text] [Related]
30. Helicobacter pylori Resistance to Triple Therapy in a Multicultural Population in New York City.
Fernandez-Perez S; Velazco G; Lenik JM; Achuo-Egbe Y; Harley J
Cureus; 2021 Nov; 13(11):e19883. PubMed ID: 34976500
[TBL] [Abstract][Full Text] [Related]
31. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance.
Smith SM; O'Morain C; McNamara D
World J Gastroenterol; 2014 Aug; 20(29):9912-21. PubMed ID: 25110421
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Three 7-Day Pantoprazole-Based Helicobacter pylori Eradication Regimens in a Mexican Population with High Metronidazole Resistance.
Dehesa M; Larisch J; Dibildox M; Di Silvio M; Lopez LH; Ramirez-Barba E; Torres J
Clin Drug Investig; 2002; 22(2):75-85. PubMed ID: 23315395
[TBL] [Abstract][Full Text] [Related]
34. First-line therapies for
De Francesco V; Bellesia A; Ridola L; Manta R; Zullo A
Ann Gastroenterol; 2017; 30(4):373-379. PubMed ID: 28655973
[No Abstract] [Full Text] [Related]
35. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies.
Selgrad M; Meissle J; Bornschein J; Kandulski A; Langner C; Varbanova M; Wex T; Tammer I; Schlüter D; Malfertheiner P
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1257-60. PubMed ID: 23863261
[TBL] [Abstract][Full Text] [Related]
36. Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis.
Chen H; Dang Y; Zhou X; Liu B; Liu S; Zhang G
Medicine (Baltimore); 2016 Feb; 95(7):e2750. PubMed ID: 26886617
[TBL] [Abstract][Full Text] [Related]
37. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance.
Lee JW; Kim N; Nam RH; Lee SM; Kwon YH; Sohn SD; Kim JM; Lee DH; Jung HC
Helicobacter; 2019 Apr; 24(2):e12561. PubMed ID: 30632237
[TBL] [Abstract][Full Text] [Related]
38. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
[TBL] [Abstract][Full Text] [Related]
39. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and Pattern of Antibiotic Resistant Strains of Helicobacter Pylori Infection in ASEAN.
Vilaichone RK; Quach DT; Yamaoka Y; Sugano K; Mahachai V
Asian Pac J Cancer Prev; 2018 May; 19(5):1411-1413. PubMed ID: 29802708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
